Immune Signature of Enhanced Functional Avidity CD8 T Cells in Vivo Induced by Vaccinia Vectored Vaccine
Authors
Affiliations
Functional avidity of T cells is a critical determinant for clearing viral infection and eliminating tumor. Understanding how functional avidity is maintained in T cells is imperative for immunotherapy. However, studies systematically characterize T cell with high functional avidity induced in vivo are still lacking. Previously, we and others found vaccinia vectored vaccine (VACV) induced antigen-specific CD8 T cells with relatively high functional avidity to those from DNA vaccine. Herein, we used functional, immune phenotyping and transcriptomic studies to define the immune signature of these CD8 T cells with high functional avidity. Antigen-specific CD8 T cells induced by VACV executed superior in vivo killing activity and displayed a distinct transcriptional profile, whereas no significantly differences were found in composition of memory sub-populations and cytokine poly-functionality. Transcriptional analyses revealed unique features of VACV induced CD8 T cells in several biological processes, including transport, cell cycle, cell communication and metabolic processes. In summary, we characterize CD8 T cells of high functional avidity induced in vivo by VACV, which not only improves our understanding of adaptive T cell immunity in VACV vaccination, but also provides clues to modulate functional avidity of CD8 T cells for T cell based immunotherapy.
CD3 downregulation identifies high-avidity human CD8 T cells.
Clutton G, Weideman A, Mischell M, Kallon S, Conrad S, Shaw F Clin Exp Immunol. 2023; 215(3):279-290.
PMID: 37950348 PMC: 10876116. DOI: 10.1093/cei/uxad124.
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
Shafer P, Kelly L, Hoyos V Front Immunol. 2022; 13:835762.
PMID: 35309357 PMC: 8928448. DOI: 10.3389/fimmu.2022.835762.
Biomechanics of T Cell Dysfunctions in Chronic Diseases.
Gunasinghe S, Peres N, Goyette J, Gaus K Front Immunol. 2021; 12:600829.
PMID: 33717081 PMC: 7948521. DOI: 10.3389/fimmu.2021.600829.
Gilfillan C, Hebeisen M, Rufer N, Speiser D Eur J Immunol. 2021; 51(6):1348-1360.
PMID: 33704770 PMC: 8252569. DOI: 10.1002/eji.202049016.
Hu Z, Jiang W, Gu L, Qiao D, Shu T, Lowrie D J Mol Med (Berl). 2019; 97(12):1685-1694.
PMID: 31786669 DOI: 10.1007/s00109-019-01844-3.